Diabetes Care Devices Market Outlook (2022-2033)

Rising Global Diabetes Prevalence and Real‑Time Monitoring Demand

The diabetes care devices market experiences its strongest growth through the worldwide diabetes epidemic, which creates a need for modern monitoring and treatment systems. Recent data show the global diabetic population exceeded 540 million in 2024, with more than 61 % of those patients requiring daily glucose monitoring to maintain glycemic control and prevent complications. The increased utilization of continuous glucose monitoring systems has reached 27 percent because the system enables users to track their glucose levels in real time, which leads to improved stability and fewer emergency medical situations. The combination of real-time data and connectivity functions allows for both remote patient management and customized healthcare solutions, which have led to a 18 percent increase in remote monitoring programs during 2024. The diabetes device market requires manufacturers to develop predictive analytics and connectivity solutions, which has resulted in manufacturers making diabetes devices essential for both medical facilities and residential use.

Technological Innovation and Connected Diabetes Care

The diabetes care devices market has a major opportunity because technology-based innovations create new applications that help people with diabetes. Advanced CGM devices, such as those integrating AI and predictive analytics, provide users with proactive glucose monitoring capabilities that extend beyond standard glucose measurement by delivering solutions which identify upcoming high or low glucose trends. The industry demonstrates this pattern through its approval of next-generation CGM products which receive authorization for extended wear and improved smart device connectivity capabilities. Digital health platforms and wearable companies are forming partnerships through their joint efforts to combine CGM data with other health metrics to develop complete metabolic health assessments. The digital systems enable clinical work reduction through their remote patient monitoring capabilities which establish customized treatment plans that benefit different patient groups.

The " Diabetes Care Devices Market Size and Forecast (2022-2033)" report provides a detailed analysis of the market covering below areas:

• Diabetes care devices market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Diabetes care devices market trends, as well as market dynamics such as drivers, restraints, and key opportunities
• Diabetes care devices market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the diabetes care devices market
• Detailed company profiles, including SWOT analysis

The geographical scope of the diabetes care devices market report is divided into five regions: North America, Asia Pacific, Europe, Middle East and Africa, and South and Central America. The diabetes care devices market in Asia Pacific is expected to grow significantly during the forecast period.

The Asia-Pacific diabetes care devices market is segmented into China, Japan, South Korea, India, Australia, New Zealand, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Taiwan, Bangladesh, and the Rest of Asia. The Asia-Pacific diabetes care devices market is experiencing robust growth, due to multiple converging factors. The rapid urbanization and changing lifestyle patterns, which two countries and Indonesia now face, have caused diabetes rates to increase sharply, especially Type 2 diabetes, thus creating a large patient base that needs permanent monitoring and medical care. The public now recognizes diabetes complications, and people understand that early detection can help them control their condition better, which has led to increased usage of home monitoring devices that include glucometers and continuous glucose monitoring systems. The regional governments by developing healthcare systems and public health programs, which enable better access to advanced diabetes treatment systems, now provide better healthcare services to both urban and semi-urban regions.

The development of smart insulin pens and AI-enabled glucose monitoring devices has resulted in affordable technology solutions, which tech-savvy users now find easy to obtain. The distribution channels, which now include online pharmacies and e-commerce platforms, have expanded their reach to remote areas, thus making their products more accessible to customers. The diabetes care devices market across Asia-Pacific continues to experience strong expansion because multiple present factors, which include rising disease rates and increasing public knowledge, along with better system development and new technological breakthroughs and improved system access.

• The report includes qualitative and quantitative data in the diabetes care devices market across product type, device type, delivery type, end user, and geography.
• The report starts with the key takeaways (chapter 2), highlighting the key trends and outlook of the diabetes care devices market.
• Chapter 3 includes the research methodology of the study.
• Chapter 4 further includes ecosystem analysis.
• Chapter 5 highlights the major industry dynamics in the diabetes care devices market, including factors that are driving the market, prevailing deterrents, potential opportunities, as well as future trends. Impact analysis of these drivers and restraints is also covered in this section.
• Chapter 6 discusses the diabetes care devices market scenario, in terms of historical market revenues, and forecast till the year 2031.
• Chapters 7 to 11 cover diabetes care devices market segments by product type, device type, delivery type, end user, and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America. They cover the market revenue forecast and factors driving the market.
• Chapter 12 describes the competitive analysis along with the heat map analysis for the key players operating in the market.
• Chapter 13 describes the industry landscape analysis. It provides detailed descriptions of business activities such as market initiatives, new developments, mergers, and joint ventures globally, along with a competitive landscape.
• Chapter 14 provides detailed profiles of the major companies operating in the diabetes care devices market. Companies have been profiled on the basis of their key facts, business descriptions, products and services, financial overview, SWOT analysis, and key developments.
• Chapter 15, i.e., the appendix is inclusive of a brief overview of the company, list of abbreviations, and disclaimer.

The diabetes care devices market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the diabetes care devices market are:

• In January 2024, the CE Mark certification for the MiniMed 780G system with Simplera Sync which includes a disposable continuously operating glucose monitoring device requires no fingerstick tests or taped application according to Medtronic plc. Simplera Sync offers users better functionality through its two-step process which allows for easier insertion while being smaller than all previous Medtronic sensors. The MiniMed 780G system represents Medtronic's finest insulin delivery system which provides automatic glucose level corrections at five-minute intervals.
• In September 2024, Senseonics Holdings, Inc. which develops and produces long-lasting implantable CGM systems for diabetics together with Ascensia Diabetes Care announced that the U.S. Food and Drug Administration (FDA) has granted approval for the next-generation Eversense 365 CGM system which monitors Type 1 and Type 2 diabetes in patients aged 18 and older. Eversense 365 is the world's first One Year CGM system, representing a significant breakthrough in diabetes technology and management.